Japan Approves First Humira Biosimilar

Mylan Will Market Fujifilm Kyowa Kirin’s Adalimumab Rival In Japan

Japan has approved its first biosimilar rival to Humira. Mylan is set to market the Fujifilm Kyowa Kirin Biologics adalimumab biosimilar, having already launched the product as Hulio in Europe.

Thumbs_Up_Japan
Japan has given the nod to its first adalimumab biosimilar • Source: Shutterstock

Japan has approved its first biosimilar rival to the blockbuster Humira (adalimumab) brand. Mylan is set to market the Fujifilm Kyowa Kirin Biologics biosimilar locally, having already launched the product as Hulio in Europe under a 2018 partnership that was expanded globally in 2019.

Mylan did not immediately respond to Generics Bulletin enquiries over launch plans for the product in Japan.

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.